Theratechnologies Inc. (THTX), Monday, announced encouraging preliminary tolerability and efficacy data from part 3 of its ongoing Phase 1b trial, evaluating sudocetaxel zendusortide in patients with advanced ovarian cancer.
The study, involving 13 participants, was divided into two arms - A and B. Both the arms had a treatment schedule of three weeks on and one week off, repeated every 28 days.
In Arm A, participants received a 1.75-mg/kg/week dose of sudocetaxel zendusortide, whereas Arm B participants received a 2.5-mg/kg/week dose on a weekly infusion.
According to the study findings, no dose-limiting toxicities were observed in either arm.
While there were no responses observed in the five Arm A participants, three of the six patients enrolled in Arm B experienced significant reductions in the CA-125 ovarian tumor marker and tumor shrinkage, with one patient achieving a complete resolution of a liver lesion, the company noted.
Based on the findings, the Medical Review Committee has unanimously recommended continued evaluation and exploration of higher doses.
Currently, Theratechnologies's stock is trading at $1.49, up 4.93 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.